pharma · Prurigo Nodularis · Uremic Pruritus · TRVI
Trevi Therapeutics
Trevi Therapeutics clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 195 Church Street, 16th Floor, New Haven, CT 06510, US
- Founded
- 2011
- Employees
- 45
- Programs
- 11
- Drugs
- 8
- Patents
- 7
Trevi Therapeutics projects
5 ClinicalTrials.gov programs sponsored by Trevi Therapeutics.
Trevi Therapeutics has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Nalbuphine ER Tablets
Trevi Therapeutics
Prurigo Nodularis
1 trial -
nalbuphine HCl ER
Trevi Therapeutics
Prurigo Nodularis
1 trial -
nalbuphine HCl ER
Trevi Therapeutics
Uremic Pruritus
2 trials -
nalbuphine HCl ER tablets 60 mg BID
Trevi Therapeutics
Uremic Pruritus
1 trial -
nalbuphine HCl ER tablets 90 mg BID
Trevi Therapeutics
Prurigo Nodularis
1 trial
Frequently asked questions
How many clinical projects does Trevi Therapeutics have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.